Anaspaz (Hyoscyamine) Dosing
The FDA-approved dosing for Anaspaz is not explicitly provided in the available evidence, which consists primarily of research studies using various hyoscyamine doses for specific procedures rather than standard therapeutic dosing guidelines.
Critical Gap in Evidence
The provided evidence does not contain the FDA drug label for Anaspaz (hyoscyamine sulfate) with standard dosing recommendations. The drug label excerpts provided 1 are for chlordiazepoxide/clidinium bromide combination capsules, not for Anaspaz/hyoscyamine.
Dosing Information from Research Studies
While not representing FDA-approved standard dosing, the research evidence shows these doses were used in clinical trials:
Adults (≥18 years):
Pediatric Dosing:
No pediatric dosing information for Anaspaz is available in the provided evidence. The pediatric guidelines 7 discuss various emergency medications but do not include hyoscyamine/Anaspaz dosing for children ages 2-12 years or adolescents ≥12 years.
Important Clinical Context
The research studies [2-4] evaluated hyoscyamine for specific indications (ureteral colic, colonoscopy, sigmoidoscopy) with mixed efficacy results. These were investigational doses, not standard therapeutic recommendations.
Recommendation
You must consult the actual FDA-approved Anaspaz drug label or a current drug reference (e.g., Lexicomp, Micromedex) for accurate age-specific dosing, as this critical information is not present in the provided evidence.